SunTrust Sees YE Catalysts for uniQure (QURE)

SunTrust Robinson Humphrey maintains Buy on uniQure BV (NASDAQ: QURE) price target of $48.00.

Analyst Ed Nash comments "We had the opportunity to host an investor group dinner with the management team of uniQure. We walked away with our confidence reinforced with regards to the potential success of the company's hemophilia B program. We believe uniQure will begin a Phase III trial sooner than Spark/Pfizer and will potentially have a first mover advantage if approved. The use of AAV5, manufacturing capability, and strong IP all give uniQure a "leg up", in our opinion. We believe the data from the dose-confirmation study by year end could further boost QURE shares."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $36.94 yesterday.

You May Also Be Interested In

• BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy
• BTIG Starts Lifeway Foods (LWAY) at Buy
• H.C. Wainwright Reiterates Buy Rating on Seaport Therapeutics (SPTX)